Kidney Compass: Navigating Clinical Trials podcast

VISIONARY 2-Year eGFR Data in IgA Nephropathy

0:00
37:57
Rewind 15 seconds
Fast Forward 15 seconds
Hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, welcome Dana Rizk, MD, professor of medicine in the Division of Nephrology at the University of Alabama at Birmingham. Rizk walks through the 24-month eGFR and safety findings from the phase 3 VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy (IgAN) in the lastest episode of Kidney Compass.

More episodes from "Kidney Compass: Navigating Clinical Trials"